Skip to content Skip to footer
Subscribe Now

NEWS

IntraGel Therapeutics and UroGen Pharma Ink Strategic Collaboration &  Investment to Advance TumoCure & Expand Sustained-Release Oncology Pipeline
Shots: IntraGel Therapeutics has entered into a strategic collaboration and investment agreement with UroGen Pharma to advance TumoCure for advanced head and neck cancer and expand the potential application of its SRGel biodegradable sustained-release platform As per the deal, UroGen will invest up to $7M in IntraGel to support the P-II development of TumoCure and…
August 21, 2026
Chai Discovery and BMS Collaborate to Enhance AI-Driven Antibody Discovery
Shots: Chai Discovery has entered a collaboration with BMS to advance the discovery of therapeutic antibodies using artificial intelligence As per the deal, BMS will leveraging Chai’s AI models and platform capabilities including its molecular folding & design models to support the discovery of antibody candidates across its portfolio and to support the development of…
August 21, 2026
Avricore Health’s HealthTab Enters Multi-Year Collaboration with Abbott to Expand Point-of-Care Testing Across the UK
Shots: Avricore Health’s HealthTab entered a multi-year collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products through the HealthTab platform across the UK, supporting the expansion of pharmacy-based testing. Under the agreement, HealthTab will distribute Abbott’s Afinion 2 Analyzer through NHS-linked pharmacies for HbA1c and lipid profile testing, while establishing a framework…
August 20, 2026
Amplitude Therapeutics and Eli Lilly Partner to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases
Shots: Amplitude and Lilly entered into a strategic research collaboration and licensing agreement to discover and develop trans-amplifying RNA (taRNA) vaccine candidates for infectious diseases. Lilly retains the option to add up to two additional infectious disease targets. The collaboration combines Amplitude’s proprietary taRNA platform with Lilly’s global development, manufacturing, regulatory, and commercialisation capabilities. Amplitude…
August 20, 2026
Lupin and Tenpoint Therapeutics Partner to Commercialize YUVEZZI in Key European Markets for Presbyopia
Shots: Lupin, through its wholly owned subsidiary VISUfarma B.V., entered into an exclusive licensing agreement with Visus Therapeutics, a wholly owned subsidiary of Tenpoint Therapeutics, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia in the European Union, United Kingdom, Switzerland, Norway, and Iceland Under the agreement, VISUfarma will hold exclusive rights…
August 20, 2026
Tolerance Bio Licenses Efineptakin Alfa from NeoImmuneTech to Advance Thymic Function and Immune Resilience Programs
Shots: Tolerance Bio entered into an exclusive license agreement with NeoImmuneTech for the development and commercialization of efineptakin alfa (NT-I7), for certain thymus-related indications in the Americas and Europe. The company also plans to initiate P-II studies evaluating the therapy for enhancement of thymic function Under the agreement, Tolerance Bio will advance efineptakin alfa alongside…
August 20, 2026
Ultragenyx Receives FDA Accelerated Approval for GENGLYCOS Gene Therapy to Treat the Underlying Cause of GSDIa
Shots: Ultragenyx reported the US FDA accelerated approval to GENGLYCOS (pariglasgene brecaparvovec-opnr; DTX401) for adults and pediatric patients (≥8yrs., n=46) with glycogen storage disease type Ia (GSDIa) The approval was supported by the P-III (GlucoGene) study, in which GENGLYCOS (n=20) demonstrated a statistically significant reduction in cornstarch requirements at 48wks. vs PBO (n=24) (p<0.001). The…
August 20, 2026
Load more